FeesSafety
Pluang+

Opus Genetics doses first patient in trial for gene therapy targeting rare childhood blindness RDH12-LCA

Company Fundamentals
19 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Opus Genetics doses first patient in trial for gene therapy targeting rare childhood blindness RDH12-LCA

Opus Genetics has dosed the first participant in its Phase 1/2 clinical trial of OPGx-RDH12, a gene therapy aimed at treating RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare inherited childhood blindness affecting about 2,500 people in the U.S. This milestone follows FDA clearance of the trial and marks the company's third gene therapy program entering clinical development. The therapy delivers a functional RDH12 gene to retinal cells to preserve vision, with safety and efficacy being evaluated. The trial is supported by a collaboration with the Global RDH12 Alliance, which includes patient advocacy groups in the U.S. and UK, aiming to accelerate treatment development for this progressive disease.

Opus Genetics dosing milestone is context for readers following health sector stocks. For readers following health stocks, here is Pluang's market snapshot as of Nov 19, 2026 18:12 WIB: Of 150 priced US health stocks, 79 rose and 64 fell. TXG was priced at USD 58.80 with a 3.03% gain and 100% buy order activity. ACB traded at USD 4.27 with a 2.95% loss and 100% sell order activity. ERAS was at USD 14.14 with a 2.76% gain and a typical hold time of 4 days.

More News

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works reported third-quarter earnings per share of $0.26, surpassing the $0.12 estimate, and revenue of $1.58 billion, above the $1.55 billion estimate. The company also announced a new $500 million share repurchase program and raised its...

Company Fundamentals
Bullish
52 minutes ago
Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal has integrated its neutral-atom quantum processors natively into Slurm's Hierarchical Resources (HRES) system, recently expanded by NVIDIA. This allows supercomputing centers to manage quantum processing units (QPUs) alongside CPUs and GPUs mo...

Market News
Bullish
56 minutes ago
SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX currently earns most of its profits from its Starlink satellite internet service, which has 13.6 million subscribers and generated $2.37 billion in operating income last quarter. However, the company is aggressively pivoting towards artificial...

Market News
Bullish
1 hour ago
TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

Despite a recent 25% drop in semiconductor stocks, TSMC and Applied Materials stand out due to their dominant market positions and growth potential. TSMC leads with a 73% share in the foundry market, benefiting from AI chip demand and planned price h...

Market News
Bullish
1 hour ago
Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

The stock market is vulnerable to a sharp correction due to rising interest rates and uncertainty in the AI industry following Nvidia CEO Jensen Huang's departure amid scandal. Inflation pressures have led the Federal Reserve to raise rates, potentia...

Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App